Physician profile
Ryan Upson
NPI 1891032439
$2,389.09
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,889 · 2022: $500.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $299.03 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $264.41 | 2021 | |
| Neurocrine Biosciences, INC. | $250.90 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $240.94 | 2021-2022 | |
| Lundbeck LLC | $207.31 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $205.33 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $167.02 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $166.92 | 2021-2022 | |
| Alkermes, INC. | $152.41 | 2021-2022 | |
| Abbvie INC. | $135.94 | 2021-2022 | |
| Eisai INC. | $86.68 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $77.31 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $32.88 | 2021 | |
| Corium, LLC | $32.11 | 2022 | |
| Ironshore Pharmaceuticals INC. | $20.51 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $18.39 | 2021 | |
| Avanir Pharmaceuticals, INC. | $16.85 | 2021 | |
| Owp Pharmaceuticals, INC. | $14.15 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Upson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.